Despite its raging success in oncology, translational barriers still plague ADC development, with preclinical activity not matching early clinical safety and efficacy readouts. 

Join this workshop to best understand preclinical development and the rationale to effectively characterize ADC safety and efficacy, thus minimizing the mismatch once you enter clinical investigation.